用于治疗尿失禁的干细胞：功能分化还是细胞因子效应？
Stem Cells for Urinary Incontinence: Functional Differentiation or Cytokine Effects?
作者信息
Gill Bradley C, Sun Daniel Z, Damaser Margot S
机构信息
Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH.
出版信息
Urology. 2018 Jul;117:9-17. doi: 10.1016/j.urology.2018.01.002. Epub 2018 Jan 12.
Abstract
Minimally invasive stem cell therapy for stress urinary incontinence may provide an effective nonsurgical treatment for this common condition. Clinical trials of periurethral stem cell injection have been under way, and basic science research has demonstrated the efficacy of both local and systemic stem cell therapies. Results differ as to whether stem cells have a therapeutic effect by differentiating into permanent, functional tissues or exert benefits through a transient presence and the secretion of regenerative factors. This review explores the fate of therapeutic stem cells for stress urinary incontinence and how this may relate to their mechanism of action.
摘要
微创干细胞疗法治疗压力性尿失禁可能为这种常见病症提供一种有效的非手术治疗方法。尿道周围干细胞注射的临床试验一直在进行，基础科学研究也已证明局部和全身干细胞疗法的有效性。关于干细胞是通过分化为永久性功能性组织发挥治疗作用，还是通过短暂存在和分泌再生因子产生益处，结果存在差异。本综述探讨了用于治疗压力性尿失禁的治疗性干细胞的命运，以及这可能与其作用机制有何关联。
相似文献
1
Stem Cells for Urinary Incontinence: Functional Differentiation or Cytokine Effects?用于治疗尿失禁的干细胞：功能分化还是细胞因子效应？
Urology. 2018 Jul;117:9-17. doi: 10.1016/j.urology.2018.01.002. Epub 2018 Jan 12.
2
Periurethral injection of autologous adipose-derived stem cells with controlled-release nerve growth factor for the treatment of stress urinary incontinence in a rat model.经尿道注射自体脂肪来源干细胞联合控释神经生长因子治疗大鼠压力性尿失禁。
Eur Urol. 2011 Jan;59(1):155-63. doi: 10.1016/j.eururo.2010.10.038. Epub 2010 Oct 26.
3
4
[Modern Therapy of Urinary Incontinence Using Muscle Stem Cells].[使用肌肉干细胞治疗尿失禁的现代疗法]
Praxis (Bern 1994). 2020 Apr;109(6):447-452. doi: 10.1024/1661-8157/a003421.
5
Development of stem cell therapy for stress urinary incontinence.干细胞治疗压力性尿失禁的研究进展。
Curr Opin Obstet Gynecol. 2012 Oct;24(5):311-7. doi: 10.1097/GCO.0b013e328357ae03.
6
Update in management of male urinary incontinence: injectables, balloons, minimally invasive approaches.男性尿失禁管理的新进展：注射剂、球囊、微创方法。
Curr Opin Urol. 2013 Nov;23(6):536-9. doi: 10.1097/01.mou.0000434592.79951.44.
7
Advances in stem cell therapy for male stress urinary incontinence.干细胞治疗男性应激性尿失禁的研究进展。
Expert Opin Biol Ther. 2019 Apr;19(4):293-300. doi: 10.1080/14712598.2019.1578343. Epub 2019 Feb 15.
8
Biological characterization of adipose-derived regenerative cells used for the treatment of stress urinary incontinence.用于治疗压力性尿失禁的脂肪来源再生细胞的生物学特性。
Int J Urol. 2021 Jan;28(1):115-124. doi: 10.1111/iju.14408. Epub 2020 Dec 1.
9
Periurethral injection of autologous adipose-derived regenerative cells for the treatment of male stress urinary incontinence: Report of three initial cases.经尿道注射自体脂肪来源的再生细胞治疗男性压力性尿失禁：三例初步报告。
Int J Urol. 2012 Jul;19(7):652-9. doi: 10.1111/j.1442-2042.2012.02999.x. Epub 2012 Mar 21.
10
The potential use of cytokines and stem cell homing signals in the treatment of stress urinary incontinence.细胞因子和干细胞归巢信号在压力性尿失禁治疗中的潜在应用。
J Urol. 2007 Apr;177(4):1227-8. doi: 10.1016/j.juro.2007.01.074.
引用本文的文献
1
The Outcome of Cell Therapy Treating Urinary Incontinence Correlates with Precise Cell Localization in the Sphincter Complex.细胞疗法治疗尿失禁的效果与括约肌复合体中细胞的精确定位相关。
Biomedicines. 2025 Apr 9;13(4):917. doi: 10.3390/biomedicines13040917.
2
Effect of controlled release of HGF on extracellular vesicle secretion by urine-derived stem cells.肝细胞生长因子控释对尿源性干细胞细胞外囊泡分泌的影响。
Front Bioeng Biotechnol. 2024 Aug 21;12:1436296. doi: 10.3389/fbioe.2024.1436296. eCollection 2024.
3
Limbal stem cells carried by a four-dimensional -printed chitosan-based scaffold for corneal epithelium injury in diabetic rabbits.用于糖尿病兔角膜上皮损伤的基于壳聚糖的四维打印支架携带的角膜缘干细胞
Front Physiol. 2024 Jun 3;15:1285850. doi: 10.3389/fphys.2024.1285850. eCollection 2024.
4
Neurobiological insights into lower urinary tract dysfunction: evaluating the role of brain-derived neurotrophic factor.下尿路功能障碍的神经生物学见解：评估脑源性神经营养因子的作用
Am J Clin Exp Urol. 2023 Dec 15;11(6):559-577. eCollection 2023.
5
Stem-cell therapy in stress urinary incontinence: A review.压力性尿失禁的干细胞治疗：综述
Tzu Chi Med J. 2022 Sep 5;35(2):111-119. doi: 10.4103/tcmj.tcmj_145_22. eCollection 2023 Apr-Jun.
6
Therapies Based on Adipose-Derived Stem Cells for Lower Urinary Tract Dysfunction: A Narrative Review.基于脂肪来源干细胞治疗下尿路功能障碍的叙述性综述
Pharmaceutics. 2022 Oct 19;14(10):2229. doi: 10.3390/pharmaceutics14102229.
7
Human primary muscle stem cells regenerate injured urethral sphincter in athymic rats.人原代肌肉干细胞在无胸腺大鼠中再生损伤的尿道括约肌。
Animal Model Exp Med. 2022 Oct;5(5):453-460. doi: 10.1002/ame2.12280. Epub 2022 Oct 8.
8
Urethral injection of dedifferentiated fat cells ameliorates sphincter damage and voiding dysfunction in a rat model of persistence stress urinary incontinence.尿道注射去分化脂肪细胞可改善持久性应激性尿失禁大鼠模型的括约肌损伤和排尿功能障碍。
Int Urol Nephrol. 2022 Apr;54(4):789-797. doi: 10.1007/s11255-021-03083-3. Epub 2022 Feb 17.
9
MSC-based therapy in female pelvic floor disorders.基于间充质干细胞的疗法在女性盆底功能障碍中的应用
Cell Biosci. 2020 Sep 10;10:104. doi: 10.1186/s13578-020-00466-4. eCollection 2020.
10
Status, challenges, and future prospects of stem cell therapy in pelvic floor disorders.干细胞疗法在盆底功能障碍中的现状、挑战及未来前景
World J Clin Cases. 2020 Apr 26;8(8):1400-1413. doi: 10.12998/wjcc.v8.i8.1400.
本文引用的文献
1
Midurethral slings in the mesh litigation era.网状物诉讼时代的中段尿道吊带术
Transl Androl Urol. 2017 Jul;6(Suppl 2):S68-S75. doi: 10.21037/tau.2017.04.06.
2
Surgical Treatment of Female Stress Urinary Incontinence: AUA/SUFU Guideline.女性压力性尿失禁的外科治疗：AUA/SUFU 指南。
J Urol. 2017 Oct;198(4):875-883. doi: 10.1016/j.juro.2017.06.061. Epub 2017 Jun 15.
3
Precise injection of human mesenchymal stromal cells in the urethral sphincter complex of Göttingen minipigs without unspecific bulking effects.在哥廷根小型猪尿道括约肌复合体中精确注射人间充质基质细胞，无非特异性填充效应。
Neurourol Urodyn. 2017 Sep;36(7):1723-1733. doi: 10.1002/nau.23182. Epub 2016 Dec 9.
4
Smooth Muscle Progenitor Cells Derived From Human Pluripotent Stem Cells Induce Histologic Changes in Injured Urethral Sphincter.源自人类多能干细胞的平滑肌祖细胞诱导受损尿道括约肌的组织学变化。
Stem Cells Transl Med. 2016 Dec;5(12):1719-1729. doi: 10.5966/sctm.2016-0035. Epub 2016 Jul 26.
5
Quality of life assessment in female patients 2 and 4 years after muscle-derived cell transplants for stress urinary incontinence treatment.肌肉来源细胞移植治疗压力性尿失禁后2年和4年女性患者的生活质量评估
Ginekol Pol. 2016;87(3):183-9. doi: 10.17772/gp/61330.
6
Electrical Stimulation Followed by Mesenchymal Stem Cells Improves Anal Sphincter Anatomy and Function in a Rat Model at a Time Remote From Injury.电刺激联合间充质干细胞可在远离损伤的时间点改善大鼠模型的肛门括约肌解剖结构和功能。
Dis Colon Rectum. 2016 May;59(5):434-42. doi: 10.1097/DCR.0000000000000548.
7
Smooth Muscle Precursor Cells Derived from Human Pluripotent Stem Cells for Treatment of Stress Urinary Incontinence.源自人多能干细胞的平滑肌前体细胞用于治疗压力性尿失禁
Stem Cells Dev. 2016 Mar 15;25(6):453-61. doi: 10.1089/scd.2015.0343.
8
Mesenchymal stem cell therapy in a rat model of birth-trauma injury: functional improvements and biodistribution.间充质干细胞疗法用于出生创伤损伤大鼠模型：功能改善与生物分布
Int Urogynecol J. 2016 Feb;27(2):291-300. doi: 10.1007/s00192-015-2831-5. Epub 2015 Sep 9.
9
The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency.骨骼肌前体细胞疗法在先天性尿道括约肌功能不全犬模型中的剂量效应安全性概况。
Stem Cells Transl Med. 2015 Mar;4(3):286-94. doi: 10.5966/sctm.2014-0114. Epub 2015 Jan 30.
10
imaging of adipose-derived mesenchymal stem cells in female nude mice after simulated childbirth injury.模拟分娩损伤后雌性裸鼠脂肪间充质干细胞的成像
Exp Ther Med. 2015 Feb;9(2):372-376. doi: 10.3892/etm.2014.2092. Epub 2014 Nov 27.
Zotero 插件